Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.jaut.2021.102598

http://scihub22266oqcxt.onion/10.1016/j.jaut.2021.102598
suck pdf from google scholar
33524876!7826092!33524876
unlimited free pdf from europmc33524876    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33524876      J+Autoimmun 2021 ; 118 (ä): 102598
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • COVID-19 convalescent plasma composition and immunological effects in severe patients #MMPMID33524876
  • Acosta-Ampudia Y; Monsalve DM; Rojas M; Rodriguez Y; Gallo JE; Salazar-Uribe JC; Santander MJ; Cala MP; Zapata W; Zapata MI; Manrique R; Pardo-Oviedo JM; Camacho B; Ramirez-Santana C; Anaya JM
  • J Autoimmun 2021[Mar]; 118 (ä): 102598 PMID33524876show ga
  • Convalescent plasma (CP) has emerged as a treatment for COVID-19. However, the composition and mechanism of action are not fully known. Therefore, we undertook a two-phase controlled study in which, first the immunological and metabolomic status of recovered and severe patients were evaluated. Secondly, the 28-day effect of CP on the immune response in severe patients was assessed. Nineteen recovered COVID-19 patients, 18 hospitalized patients with severe disease, and 16 pre-pandemic controls were included. Patients with severe disease were treated with CP transfusion and standard therapy (i.e., plasma recipients, n = 9) or standard therapy alone (n = 9). Clinical and biological assessments were done on day 0 and during follow-up on days 4, 7, 14, and 28. Clinical parameters, viral load, total immunoglobulin (Ig) G and IgA anti-S1-SARS-CoV-2 antibodies, neutralizing antibodies (NAbs), autoantibodies, cytokines, T and B cells, and metabolomic and lipidomic profiles were examined. Total IgG and IgA anti-S1-SARS-CoV-2 antibodies were key factors for CP selection and correlated with NAbs. In severe COVID-19 patients, mostly interleukin (IL)-6 (P = <0.0001), IL-10 (P = <0.0001), IP-10 (P = <0.0001), fatty acyls and glycerophospholipids were higher than in recovered patients. Latent autoimmunity and anti-IFN-alpha antibodies were observed in both recovered and severe patients. COVID-19 CP induced an early but transient cytokine profile modification and increases IgG anti-S1-SARS-CoV-2 antibodies. At day 28 post-transfusion, a decrease in activated, effector and effector memory CD4(+) (P < 0.05) and activated and effector CD8(+) (P < 0.01) T cells and naive B cells (P = 0.001), and an increase in non-classical memory B cells (P=<0.0001) and central memory CD4(+) T cells (P = 0.0252) were observed. Moreover, IL-6/IFN-gamma (P = 0.0089) and IL-6/IL-10 (P = 0.0180) ratios decreased in plasma recipients compared to those who received standard therapy alone. These results may have therapeutic implications and justify further post-COVID-19 studies.
  • |*SARS-CoV-2[MESH]
  • |Adult[MESH]
  • |Antibodies, Neutralizing/*blood[MESH]
  • |Antibodies, Viral/*blood[MESH]
  • |B-Lymphocytes/metabolism[MESH]
  • |CD4-Positive T-Lymphocytes/metabolism[MESH]
  • |CD8-Positive T-Lymphocytes/metabolism[MESH]
  • |COVID-19 Serotherapy[MESH]
  • |COVID-19/blood/*therapy[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Immunization, Passive[MESH]
  • |Interleukin-10/*blood[MESH]
  • |Interleukin-6/*blood[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box